SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jibacoa who wrote (639)2/21/2002 11:53:14 PM
From: tuck  Read Replies (1) of 1005
 
Bernard,

I very nearly sold BLUE HPs INGN holdings for another swing trade. For some reason, the comment by new hire Talbott kept my finger off of the sell button.

>>Max W. Talbott, Ph.D., Introgen's senior vice president of worldwide commercial development said, ``After almost twenty clinical studies, the product development phase of Adenoviral p53 ADVEXIN® is nearing completion. Introgen is now implementing pre-marketing strategies in preparation for the approval of this revolutionary cancer therapeutic.''<<

This seems optimistic. I would imagine that the serious biofreaks here don't think approval is slam dunk. Just because they're gearing up and naming the drug doesn't mean they'll get it approved. Just ask CLPA, among others. I thought all this, and didn't sell. But a further bounce, and I will.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News